Sunday, August 25, 2019

Abstract: Evaluation of the Effect of Cannabidiol on Osteoarthritis-Associated Pain in Dogs—A Pilot Study



S. Mejia, F.M. Duerr, S. McGrath

Introduction: There is a lack of research evaluating the efficacy of cannabidiol (CBD) for treatment of osteoarthritis-associated pain using objective outcome measures. This pilot study was designed to evaluate the effect of CBD on pain associated with canine osteoarthritis.

Materials and Methods: Client-owned dogs with radiographically confirmed osteoarthritis were enrolled in this prospective, double-blinded, crossover, placebo-controlled study. Outcome measures included serum chemistry, weekly total activity counts (AC), clinical metrology instruments (CMI), and objective gait analysis (OGA). Baseline data were acquired for four weeks prior to initiation of the first treatment. Patients were randomly allocated to either placebo or oral CBD oil treatment for the first six weeks, then treated for the subsequent six weeks with the opposite treatment.

Results: Twenty-three dogs, medium-large breed dogs, were enrolled. Fourteen dogs displayed elevation in liver enzymes associated with CBD treatment. Significant differences between treatment groups were identified for several CMI and OGA time point comparisons. However, there was a lack of consistency amongst the different outcome measures.

Discussion/Conclusion: This pilot study identified differences in some outcome measures suggesting that CBD may benefit dogs with osteoarthritis-associated pain. However, adequately powered studies with a larger sample size are needed to confirm this suggestion. Further evaluation of the clinical implications of the observed liver enzyme elevation, particularly with long-term administration, is necessary.

Acknowledgment: This project was funded by Applied Basic Science Corporation. The senior author is part-owner of this company.

Vet Comp Orthop Traumatol 2019; 32(S 04): A13-A24
DOI: 10.1055/s-0039-1692272



ABOUT APPLIED BASIC SCIENCE CORP.
Our company, ABSC Organics (Applied Basic Science Corporation), was founded to research the therapeutic benefits of our hemp hybrid plant oil extract in pets who suffer from epileptic seizures, joint pain from osteoarthritis, and a host of other conditions…and then manufacture trustworthy products to provide symptomatic relief.

ABSC Pure Organic CBD Oil™ (formerly called C.H.O. Pet Tincture) is our first product, and the only one for pets to undergo multiple clinical trials at the Colorado State University College of Veterinary Medicine and Biomedical Sciences, one of the country’s leading veterinary research institutions. We sponsor these clinical trials to demonstrate scientifically that our ABSC Pure Organic CBD Oil™ compound is efficacious for epilepsy, osteoarthritis and pain management.

We are at the forefront of veterinary research and aim to be looked upon as the gold standard when it comes to pet products. Based on scientific research, veterinarians will be able to recommend ABSC Organics products with confidence and pet owners will know that there is trusted science behind ABSC Pure Organic CBD Oil™.

ABSC ORGANICS SPONSORS CLINICAL TRIALS AT COLORADO STATE UNIVERSITY
Other companies make claims. We sponsor the clinical research.

ABDC Organics believes in our product and in the power of CBD to improve your pet’s wellness and quality of life. But we know there’s a difference between belief and proof–between anecdotal stories and clinical evidence. We care about that difference, and we care about pets.That’s why we’re the only veterinary CBD company who has sponsored a Phase One Safety and Toxicity Study.
ABSC Pure Organic CBD Oil: Proven safe and well-tolerated in the first and only veterinary safety trial.

With ABSC sponsorship, Colorado State University’s College of Veterinary Medicine and Biomedical Sciences took the lead in veterinary CBD research in 2016. Using our product, Dr. Stephanie McGrath and her team at CSU investigated the safety of specified combinations and delivery methods of our hemp-hybrid oil extract in dogs. The results confirmed that dogs tolerated clinical doses of the compound found in C.H.O. Pet Tincture without adverse effects. These results were presented at the Institute of Cannabis Research Conference at CSU-Pueblo on April 29, 2017, and were published in the Fall 2018 issue of the Journal of the American Holistic Veterinary Medical Association.
Phase 2 Clinical Trials for Epilepsy and Arthritis Using ABSC Pure Organic CBD Oil

Dr. McGrath completed a pilot epilepsy study in 2018, and the promising results of that study were published in the June 1 issue of the Journal of the American Veterinary Medical Association. A larger epilepsy study, sponsored by the AKC Canine Health Foundation, is ongoing at CSU, as is an arthritis study. In each study, ABSC is supplying the CBD oil–the very same CBD oil you can buy for your pet here on our site.

Link: https://petpainfree.com/about-us/

Tecumseh Approved.


No comments:

Post a Comment